Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I can't say that you ARE reading it wrong, sosjtb.
"As soon as practicable after payment in full of, or reserve for, all other Allowed Claims, the Liquidating Trust shall
pay to each holder of an Allowed Subordinated Claim or an Allowed Existing Equity Interest its pro rata share of any
remaining amounts in the Liquidating Trust subject to the terms and conditions of this Combined Plan and Disclosure
Statement, the Liquidating Trust Agreement, and the Bankruptcy Code. No distribution to Class 4 (Subordinated
Claims) or Class 5 (Existing Equity Interests) is anticipated."
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1074462&projectCode=HUM&docketNumber=226&source=DM
p 33/65
But, you certainly COULD BE reading it wrong.
"As soon as practicable after payment in full of, or reserve for, all other Allowed Claims, the Liquidating Trust shall
pay to each holder of an Allowed Subordinated Claim or an Allowed Existing Equity Interest its pro rata share of any
remaining amounts in the Liquidating Trust subject to the terms and conditions of this Combined Plan and Disclosure
Statement, the Liquidating Trust Agreement, and the Bankruptcy Code. No distribution to Class 4 (Subordinated
Claims) or Class 5 (Existing Equity Interests) is anticipated...
there is no assurance that the Liquidating Trust will be successful in prosecuting any Cause of Action or generate sufficient
proceeds from the Causes of Action for Distribution. "
p 33/65 p 35/65
The case remains a CH11, and the recall of the loaned shares, especially if Novavax purchases the lenz/vaccine cocktail, or we combine/partner/merge through Taran into Sanofi, and get regulatory approval from Australia, perhaps with a PRV, we could easily see Ed Dowd announce a target price of $67 for our shares.
"The new Humanigen may be stronger than I expected."
At one point, I actually questioned why the CH11 bankruptcy would be necessary. If Humanigen owns 110M of the 119M shares they have issued, and if our float of 229M shares is 192% of our OS, that could only mean that Humanigen has loaned the excess shares in our market. If so, Humanigen would be positioned to issue a recall of their loaned shares, and cause an even more massive short squeeze than they did as Kalobios.
I see no change in those circumstances.
I think Humanigen has held off recalling their loaned shares, until news, such as in regards to regulatory approval or authorization of lenzilumab, or news regarding a business combination/merger/partnership, was ready to be announced. This extended delay caused the financial constraints that forced the CH11 (as the US regulators tried to force us out of business, and protect their financial investment in Moderna, and promote their mRNA ideology, in my opinion).
I really think that Novavax may have used lenz as an enhancement in their prototype vaccine. I also think that Sanofi graduated, as Gracell did, from Humanigen's incubation of their their products, used with lenz for enhanced safety and efficacy. And I note how this CH11 is nearing completion as Sanofi prepares to spin-off their healthcare division, and the PREACH-M trial results are placed for regulatory approval in Australia, perhaps with a Priority Review Voucher worth ~$100M.
The only things that have changed are:
We may have partnership interests from Novavax, PREACH-M (and/or Sanofi), and Gracell (and perhaps AstraZeneca), exerting authorization approval of lenz from Regulators (probably overseas).
We have no secured debt obligations.
We have non-debtor Humanigen subsidiaries prepared for possible merger use in the UK, Australia, and the Republic of Ireland.
And we have shocking safety and efficacy failures, to include vaccine injuries and excess deaths, caused by the standard of care currently in use.
I'm very optimistic, and I believe that Humanigen has never been stronger than we are now.
First of all, thank you for sharing that link, GURUBK. I'd certainly like to see our equity tied again to the IP rights, even if just by exclusive license. But I just don't think that this is going to happen solely by acquisition. Fine with me, if it does. The new Humanigen may be stronger than I expected. I just thought, and still think, that we'll see a merger, business combination, or partnerships factor into our new course, as well.
I'm interpreting an entirely different vibe, dlog. It seems that antibodies derived from vaccine-induced infection are weakening, and at the same time, the virulence of the next coronavirus to circulate, will be significantly worse than any strain or type that we have seen so far.
If so, then most of the covid that lenz will have to fight will be vaccine-induced, AND more deadly, unless the FDA prohibits mRNA vaccines, and authorizes lenz, before the next variant begins to circulate. I am very curious to see if lenz will be capable of restoring the the immune response in this scenario.
I think it would be naive to think that Moderna, with the $2.5B US government investment in their company, has (..."nothing to do with our company"). The US government, in my opinion, is keeping lenz out of the covid market, to safeguard their Moderna investment, and misplaced faith in mRNA technology.
There's a reason the charges the UK wants to file regarding the forced acceptance of mRNA vaccines, include charges of murder. I hope TX AG Ken Paxton also files criminal charges against Pfizer, Moderna, Lancet, Thorax, NIAID, the NIH, the CDC, and the FDA.
Easy come, easy go.
"Moderna has scored $2.48 billion in R&D and supply funding from the U.S. government for its program."
https://www.fiercepharma.com/pharma/after-nearly-1b-research-funding-moderna-takes-1-5b-coronavirus-vaccine-order-from-u-s
"Moderna halts plans to build Kenya vaccine plant as Covid shot demand plunges
PUBLISHED THU, APR 11 2024...
The biotech company said it has not received any vaccine orders for Africa since 2022 and has taken more than $1 billion in losses and write-downs related to the cancellation of previous orders from the continent.
https://www.cnbc.com/2024/04/11/moderna-halts-kenya-vaccine-plant-plans-as-covid-shot-demand-plunges.html
The lack of demand for mRNA covid vaccines in Africa is noteworthy.
"This study shows that the highest number of cases per million population was recorded in Europe, while the trend of new cases is lowest in Africa. The mortality rates in different continents were as follows: North America 4.57%, Europe 3.74%, South America 3.87%, Africa 3.49%, Oceania and Asia less than 2%."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157209/#:~:text=Results%3A%20This%20study%20shows%20that,cases%20is%20lowest%20in%20Africa.
It's frustrating to me, as a US citizen, to see our tax dollars squandered in support of deadly mRNA vaccine development. It's even more frustrating to me, as a US investor in Humanigen, to see Lenzilumab side-lined from the opportunity of being used as a covid traditional-vaccine-enhancement and therapeutic treatment, despite Lenzilumab's superior safety and efficacy peer-reviewed trial results.
I was glad to hear Dr. Kelly Victory interview Ed Dowd recently. Ed is a former portfolio manager at Blackrock, and I believe they may still maintain a position with Humanigen.
I've come to enjoy reading clinical trial reviews, and following the logic the trial investigators use in writing their findings. But Ed opened a new perspective on the logic he uses to make investment decisions, such as in biotech (continuing with Humanigen)? I like the way in which Ed explained his estimation of excess deaths, which brought a sharp focus on the astounding increase in excess deaths in the younger population. And another thing I really like is that he didn't just focus on covid. He noted the developments in neurological and cancer indications, as well.
I think lenz has tremendous opportunities in preventing and/or treating all three indications. I've been saying that for several years. And I really appreciated hearing a financial guy express his conclusions in this regard.
Regarding Dr. McCullough's congressional testimony about a lack of recommended covid treatment protocols, we know that in 2021, the NIH did recognize the substantial improvement lenzilumab demonstrated in treating hospitalized covid patients.
""Preliminary data from a double-blind, placebo-controlled randomized trial of lenzilumab did show a significant improvement in the primary endpoint of ventilator-free survival through Day 28 among those who received the GM-CSF inhibitor."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165682015
Since then, and as now, there has been no justification for the US and UK Regulators to negligently permit thousands of preventable deaths every week. Those deaths should be added to the number of "excess deaths" due to the mRNA vaccines, because keeping lenz off the market is only to protect the covid profits from the Pfizer and Moderna mRNA vaccines (and the financial investments in those companies made by the US and German governments).
"Sanofi needs to spin-off their healthcare sector, and we saw the S-8 regarding the Securities to be offered to employees in employee benefit plans filed today."
Other Sanofi news hitting the wire today was in regards to their on-going trial to treat Parkinson's Disease.
"A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the New England Journal of Medicine reported on Thursday."
https://www.morningstar.com/news/marketwatch/20240404312/diabetes-medication-appears-to-slow-progress-of-parkinsons-disease-in-french-backed-trial
Loss of motor control completely changes the quality of life for affected patients. I hope lenz may have a role in improving the efficacy of Sanofi's lixisenatide.
If, by some miracle, certain of the conclusions I have drawn develop as I surmised, then the counter-parties to those events need to complete their tasks, in addition to Humanigen doing the same. Baudax needs to complete their CH11, and hopefully sell Tera-Immune to us. Novavax may need to get additional regulatory approval or authorization to use lenz as their prototype vaccine enhancement. Sanofi needs to spin-off their healthcare sector, and we saw the S-8 regarding the Securities to be offered to employees in employee benefit plans filed today.
Humanigen has never been stronger that we are now. And the world will be a better place as we step into our rightful covid and oncology positions.
And no CH7. So the bankruptcy court judge does not agree with your assessment of Humanigen's prospects and future. The company is restructuring, under CH11. Give it a minute.
Sanofi filed an S-8 securities Registration Statement today. I think Sanofi may be our most-tenured shareholder, and that their oncology market could be enhanced by lenzilumab, such as we have seen in CMML. Sanofi previously announced plans to spin-off their healthcare sector, and I am excited about the partnership opportunity this could provide to Humanigen/Taran.
https://www.sec.gov/Archives/edgar/data/1121404/000119312524086673/d803515ds8.htm
The filing notes that, "The information required by Item 1 and Item 2 of Part I of Form S-8 is omitted from this filing..."
The type of information withheld, if I am reading the prospectus instructions correctly, can be found on pages 5-7 in the following link.
https://www.sec.gov/files/forms-8.pdf
You're missing the point I was making, which is that worldwide, the majority of the covid vaccines are non-mRNA-based, and I think they represent a large market for our patented method of vaccine enhancement. There is nothing "off-topic" about that, even if some staff of government agencies, such as NIH or USAMRIID, continue to promote mRNA vaccines, which pose increased risk of deadly consequences, not only to this generation, but to the unborn of the next, as well.
"What do these companies have to do with HGEN?"
Most vaccine manufacturers don't use mRNA technology, they use traditional methodology, and incorporate an inactive form of the virus, for example. That's what Novavax does, and they are the only non-mRNA vaccine manufacturer authorized in the US.
The majority of the overseas vaccine manufacturers should be candidates to use lenz as an enhancement to their vaccines. We patented the process for this application, as I've shown before.
"METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY
Publication number: 20230109208
Abstract: The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
Type: Application
Filed: March 8, 2021
Publication date: April 6, 2023
Applicant: HUMANIGEN, INC.
Inventors: Cameron DURRANT, Dale CHAPPELL"
https://patents.justia.com/assignee/humanigen-inc
It is not accurate to consider the subject of vaccine enhancement as "off topic." Quite the contrary, vaccine enhancement is THE MAIN OPPORTUNITY I am hoping to see Humanigen capture.
The only argument the antagonists have is always centered around the fact that none of the developments I fully expect to see realized have, as yet, come to pass. Instead, there is, "Not a peep from management."
I haven't seen anything disproven that was in the Top Line Data of the LIVE-AIR trial. Not only were those trial results verified by the Lancet peer-review, they were bolstered by the Thorax peer-review, based upon patient stratification by CRP levels.
I would link, for the 100th time, Humanigen's home page, with access to the Lancet and Thorax peer reviews, but I am now getting an error message trying to do so.
"Looks like this domain isn't
connected to a website yet"
https://www.humanigen.com/
All the tabs associated with the home page are accessible (Other, News, Events, etc).
https://ir.humanigen.com/English/news/default.aspx
I wonder if the Home page is getting a facelift.
And what? Am I supposed to be worried about that? That's the nature of postulating, based upon the reasoning of what is observed.
People are entirely free to think what they will, or to not think about Humanigen, at all, if that's what they want to do. But to me, it's a big deal to suffer the abuse of discretionary authority, by the very government intended to prevent the abuse of their citizens. By all means, that is true in the financial sense, where the SEC routinely ignores illegality by everyone, except for the alleged violations by the principals of the victimized companies.
But in a profoundly worse sense, as I learned here, agencies such as NIAID, the NIH, and the FDA, intentionally abuse their discretionary authority, with full knowledge of the immoral loss of life that would be prevented, were these agencies to discharge their duties faithfully. And, "...every day that goes by (I am right)," about families suffering the needless loss of a loved one.
Our share structure was designed to counteract the naked shorting of our shares, and to severely punish the perpetrators, even in the absence of fiduciary duty by the SEC. This defensive mechanism will result in the recall of Humanigen's loaned shares, or, it may be effected simply by a merger. Regardless, it should not even be a contingency for which management had to plan, and meticulously execute over a period of years. Our management has fought more battles than we'll ever know about, perhaps like in regards to our venture in Wuhan.
I think pieces are continuing to fall into place, which may include Tera-Immune, Novavax, and Sanofi, plus mergers or partnerships, including those based on the PREACH-M and RATiNG trials. Of course I'd like to know WHEN these developments will occur. But I have no reason to waste my time writing posts about how meaningless these developments will be to Humanigen.
What benefit will Taran get from the recall of the loaned shares?
Taran holds the IP rights, and Humanigen is likely holding ~90% of all the shares the company issued, with a float of 192% of the OS.
Let's just see how the reorganization develops. Humanigen is sure to maintain majority control, if necessary.
In May of 2021, #DR. PETER MCCULLOUGH, who testified about a lack of covid treatment options in front of both the national, as well as the Texas legisative oversight committees, questioned why there were no defined covid treatment protocols established. He specifically questioned where guidance was offered by The Mayo Clinic.
see the discussion from minute marks 14:30 - 15:30.
https://www.bitchute.com/video/gDXcWb4tgAkj/
I can assure Dr. McCullough that Mayo clinical trial investigators were fully engaged in the effort to bring a safe and effective covid therapeutic to market. Several of their trial investigators, working with Humanigen, led a Phase III trial of Humanigen's Lenzilumab, concluding with tremendous success (HR 1.54).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635458/
I think that #Dr. John Campbell, an English doctor I greatly admire for his fact-based research and reporting, would be even more impressed with Humanigen's reporting of outcomes based on CRP levels, which Humanigen established as a biomarker. Those results were peer-reviewed by Thorax, as shown on page 5.
"Effect of CRP<150 mg/L on SWOV and secondary endpoints in
LIVE-AIR
In participants with baseline CRP <150 mg/L, lenzilumab
improved the likelihood of SWOV compared with placebo
(HR: 2.54; 95% CI 1.46 to 4.41; nominal p=0.0009;"
https://thorax.bmj.com/content/thoraxjnl/early/2022/07/05/thoraxjnl-2022-218744.full.pdf
Humanigen's home page reflects this information, as well as the peer-review by Lancet.
https://www.humanigen.com/
Additional review established Hazard Ratios of between 3.0 - 3.4.
It has been my belief that the FDA's refusal to authorize lenzilumab (lenz) amounted to willful negligence, if not criminal negligence. Mr. Andrew Bridgen, MP, went even further. I ask #Texas Attorney General Ken Paxton to consider Mr. Bridgen's letter to Scotland yard in this regard. Texas Medicaid funds should not be used for mRNA vaccines that are resulting in more excess deaths in one year, than the number of soldiers killed in all American wars combined.
https://twitter.com/ABridgen/status/1765069935603306651/photo/1
There remains the indication for which lenzilumab was intended, and in which it has demonstrated tremendous promise. And I hope that lenz will be very successful in treating cancers, such as CMML.
But there remains two realities. First is, that the world has no safe and effective covid preventative. And secondly, there is no variant-agnostic therapeutic for covid, let alone one that could imbue an appropriate immune response against future infections.
The fact that excess deaths are attributed to mRNA vaccines, WHICH ARE STILL BEING ADMINISTERED AND ENCOURAGED, is another reason that the Novavax vaccine, in it's best form, has to be brought to market, with it's lenz enhancement. In less than a year, excess deaths from mRNA vaccines have cost more lives than all the soldiers lost in all the battles, combined, in the US.
And we are welcoming illegal immigrants by the tens of thousands, even though their countrymen have already been discovered operating biotechs on our soil, designed to spread covid and a variety of lethal diseases across our land.
The tracks on which the train has left don't just run one way. And at the least, we need to be prepared for when the train returns.
I think management is working on the application of their lenz/vaccine/anti-viral patented process. Novavax is the only US-based covid vaccine manufacturer with a traditional vaccine, which I think would be compatible for use with lenz as an enhancement.
If Humanigen has about $4M worth of lenz in-process of being manufactured, that might be enough for a re-formulated version of lenz to be administered either orally or subcutaneously, along with millions, even tens of millions, of Nuvaxovid vaccines.
I can only tell you what I think management may be working on. This is it, in large part.
Novavax issues a second set of stock options in two weeks.
https://www.sec.gov/cgi-bin/browse-edgar?company=novavax&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
On March 11th, Novavax issued the following Press Release (which I didn't see highlighted by the FDA's site).
https://ir.novavax.com/press-releases/Canada-National-Advisory-Committee-Publishes-Recommendation-for-Use-of-Novavaxs-Nuvaxovid-TM-XBB-1-5-COVID-19-Vaccine
https://newsfilter.io/
Regarding "Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)."
"Early reports from studies with patients with long COVID suggests a constellation of symptoms with similarities to another chronic medical illness-myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). A review study comparing and contrasting ME/CFS with reported symptoms of long COVID may yield mutualistic insight into the characterization and management of both conditions."
https://pubmed.ncbi.nlm.nih.gov/33925784/
I listened to an interview of Dr. Pierre Kory, who discussed Long Covid (which he says is mainly Long Vax), and says that what we're calling Long Covid is the same, or about the same, as ME/CSF, and he mentioned that Epstein-Barr was another similar indication. And I got to thinking about lenzilumab being considered for this, at one point. But more specifically, I wondered HOW lenz may be effective in treatment of this indication. Despite the similarities of Long Covid to mono, how would lenz improve CFS in patients with HLA from mono?
But he also said something of more importance to Humanigen and the shareholders. As we noted in real time, both Lancet and Thorax took exceptionally long times to complete the publications of their peer reviews, even though the results of both were stellar. Dr. Kori also noted issues regarding the medical journals, and went so far as to state his opinion that this is now where the degradation of the medical field starts. Further, he went on to say that RFK, Jr., said that he would summon the chief editors of the medical journals into his office, if elected, and file RICO charges against them, if they didn't restore integrity to their publications.
So, I think this could be further evidence of management's conviction, and lenzilumab's safety and efficacy, if Dr. Kori is right. Management may have had to fight to get fair and honest assessments of lenzilumab's performance. Something caused the extremely lengthy review times, and lenz is a profit killer for Pfizer and Moderna.
I had earlier reported an interview of Steve Kirsch, whose study revealed that autism is totally caused by vaccines, and has been, for years.
What these doctors are saying is important.
However, Tucker conducted both interviews. I think it's irrelevant to the information being conveyed by the doctors. But in this post, I included an NIH corroborative study to help focus on the subject.
I'd like to think that macro-level medical considerations do not have a hand in what transpires here. But as I look forward to a pathway of consensus regarding mRNA vaccines, I also anticipate that a new division will develop in regards to the WHO's role in dictating how our healthcare system functions in the United States. So things may get worse before they get better, if they are able to get better. I'm not optimistic. I don't trust our own federal government to represent our interest, and I suspect a WHO-directed role in the US and world-wide will have an unfortunate amount of support from the British and American public. Objectivity could become further constrained, especially on a small biotech message board.
Let's hope for the best, Brother! For the medical community to awaken to the value of lenz as a traditional vaccine-enhancement, as well as a therapeutic, will be a good thing!
AstraZeneca vaccine victims win court decision for damages, brought on violation of the Consumer Protection Act, and negating AZ's impunity. Will other vaccine manufacturers likewise face damages?
Actually, I have begun 'ignoring' this guy (or these guys) when I see them arrive with a brand new nickname, and an agenda. I see the material on stocktwits, and I gain nothing by seeing it again here. Historically, I never had any poster on ignore, despite so many people advising me to ignore this poster, or that one, over the years. But, Ihub offers the 'ignore' function, and for these virgin antagonists, I use the option to ignore them. There are other, more important issues to focus on.
Actually, Chaplain, I haven't deleted any of the posts, lately, many of which were mine. DTG hasn't, either.
If there is a problem, then there is also a reason for the problem.
And any such problem is beyond my authority to fix. I've tried, to the extent that I can. The present situation is unfortunate, and I hope we can return to the fairly good order we had.
Yes, I am saying that we can resubmit the EUA, and obtain a favorable decision, with the data, as written. Adding additional data from the ACTIV-5 patients in ordinal scale 5, and adding the PREACH-M trial results, would just be window dressing, and allow some face-saving for the FDA.
Our LIVE-AIR trial data was sufficient in volume, and exemplary in result. The trial results stand on their own. That fact is irrefutable, and I stand by that conclusion.
Thousands of people are still suffering preventable deaths from covid every week. So to me, there is nothing comical about the facts.
Doctors, independently, know how corrupt the FDA is, and they don't speak out. But I think they will, when the WHO starts dictating how they are to run their practices, and treat their patients. I don't know how woke the AMA is, but I hope they will be forced by their membership to defend their medical sovereignty.
The data from the LIVE-AIR patient population would be of sufficient volume for the FDA to make a regulatory decision. Trial size was established in consultation between the FDA and management.
The NIH ACTIV-5 trial tested late stage patients, including patients who had, or were on, IMV. The FDA even included patients on ECMO, whose outcomes were not to be factored into the trial results.
No new trial is required for an EUA. We should be able to extract ACTIV-5 results for their patients who were in ordinal scale 5, and use those results as an adjunct to the LIVE-AIR trial results, if necessary. The ACTIV-5 patients in ordinal scales 6 and 7 were too progressed in disease severity, and were not included in LIVE-AIR. We also have safety and efficacy data from lenz on the PREACH-M study, which may soon win approval in Australia, and all of this data could be included in a resubmission of our EUA application. I think our OS is already higher than management wants, and I doubt they will reverse split, even at 1:5. There will be no need to do so, anyway, after the loaned shares are recalled, and we could even see a forward split, which I hope we don't, even f it would be temporary.
Welcome to the room, SorcererGuru44, and thank you for your considerate post.
Good news for Invivyd (IVVD), and signals Regulatory stance on mAbs.
"March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc...today announced interim exploratory COVID-19 clinical event data for VYD222, an investigational, monoclonal antibody (mAb) in development for the pre-exposure prophylaxis of COVID-19."
https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-interim-exploratory-data-vyd222-ongoing-canopy
Invivyd is defining 'pre-exposure' differently than I am accustomed to seeing. They are not saying their mAb is for covid-naive patients. They're saying just the opposite.
"Exploratory data such as provided in today’s update are important for broad reflection as they represent some of the first data from a clinical trial conducted with a monoclonal antibody in a population that has acquired prior immune exposure from either vaccination or natural infection. By contrast, studies of prior authorized COVID-19 PrEP mAbs largely relied on participants required by protocol to be naïve to vaccination or prior infection." I guess the mass vaccination assault expanded the allowable definition of 'pre-exposure prophylaxis.'
In addition to the above Release Details, Invivyd also issued Release Details, which mentions the EUA.
https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-fda-authorization-emergency-use-pemgardatm
I'm actually encouraged by this.
"A PREP Act declaration is specifically for the purpose of providing immunity from liability"
https://aspr.hhs.gov/legal/PREPact/Pages/default.aspx
It only makes sense to have an alternative, traditional vaccine, available to meet healthcare demands, in the event that mRNA vaccine manufacturers withdraw from the market, when PREP Act protection expires. The only traditional vaccine approved for use in the US is the Novavax vaccine. If the safety and efficacy of that vaccine proves to be enhanced by Humanigen's patented methodology, using lenzilumab, then the company needs to be prepared to meet that demand.
Not only is the subject germane, the issue is critical. We cannot let a highly lethal virus attach to receptor cells, and if they do, we need to combat the effects of that infection vigorously and effectively, using lenzilumab, in both processes. Lenzilumab showed outstanding results when administered early. The LIVE-AIR trial met the primary endpoint, and those results have been peer-reviewed by both Lancet and Thorax. The company has a history of treatment data for the product, even preceding Covid.
You could be absolutely right, dlog.
Because I believe in the huge potential of lenz to effectively treat, and then to possibly prevent, a huge number of indications, and also because I believe in the good character of our management, I have made it my objective to try to understand what this management team is doing to get their lenz into the market. And I have shared my conclusions and opinions here.
Yes, there would have been benefit with an earlier recall of the loaned shares. It would have amounted to a blip on the radar. Even if it staved off the bankruptcy, the momentum would not have been sustained, without news leading to our ability to generate a revenue stream.
In the US, and in the UK, we're looking for regulatory approval for lenz to treat covid. That would cause the FDA and the MHRA to destroy the markets for Pfizer and Moderna, who provide the vast majority of the regulators' operating funds. It would also threaten the value of the intellectual property OWNED BY THE REGULATORS in the Pfizer and Moderna mRNA vaccines. Regulators would be slicing their own financial throats by approving Humanigen's lenzilumab, and the Novavax vaccine that uses lenz as an enhancement.
We have to capitalize on the IND authorization by having partners use lenz under IND for their vaccine and CAR-T products. We also need to exploit our opportunity for regulatory approval of lenz from Australia, to treat CMML. It's almost "game-over" for the attempts to deny our revenue stream. We will prevail. It would be an absolute catastrophe to use mRNA technology to fight a virus that could have 100% mortality, such as the Pangolin Coronavirus.
We need to see regulatory approval of lenz, which is most likely to first come from Australia. And the flood gates will then be open.
And that's when management can recall their loaned shares to the fullest monetary advantage.
I think Shkreli executed the recall of the loaned shares to re-pay his hedge fund clients from the short squeeze proceeds. Regardless of whether I over-estimated his character, or not, our short squeeze proceeds will go to funding our operational requirements, and likely regain compliance with OTC requirements for quotation, before moving back to Nasdaq.
Novavax's financial condition can do a complete reversal, if their prototype vaccine incorporated a lenz enhancement.
Anyway, once the pieces are in place, then will be the time to evaluate what "...cam has shown..."
My tenacity is just a reflection of my conviction in the character of our management, and in the safety and efficacy of lenz, which is poised to be enthusiastically embraced by the medical community, for a whole host of indications. We've never been stronger, but we will be.
You and I both posted here initially in 2015, so your opinion of me is based on a pretty complete awareness of my conclusions. I may have been able to make a more complete case, for instance, in regards to the share recall, perhaps if those records weren't sealed, and if we saw the charges against Dale's entities. The SEC didn't waste any time after the Kalobios squeeze, and charges against Dale's entities go all the way back to the very time that we became Humanigen. Still, I think Dale very likely won his Appeal. The share structure was managed meticulously, and I believe we will see a float of ~229M shares, which will cause a monster short squeeze when the loaned shares are recalled.
You are correct in saying that an opportunity with Novavax exists only in my head. There's been no sign of it otherwise. But they are the prime candidate that would qualify to use our lenz/vaccine patent, and I think they will have that opportunity as the deadly mRNA vaccines are losing market share, even before the Humanigen/Novavax product comes to market.
Hopefully, we have a pretty decent revenue stream from Gracell, and also hopefully we will be able to snag Tera-Immune, especially if Sanofi expands our opportunity to use the Treg process. Sanofi has always had a complimentary product line to Humanigen, and I look forward to the spin-off of their healthcare business. Don't discount that potential. They were here even before we showed up in 2015.
"I don't think there is any way in hell that Pfizer and Moderna will stay in the covid vaccine market past the end of the year, and run the risk of putting their mRNA vaccines into the market, without immunity from prosecution."
We'll see if that proves to be the case. It would definitely mean admitting defeat on the course that Pfizer, Moderna, and the FDA have been mandating.
And in the UK, I see what could be further recognition that the wrong covid treatment course was chosen. The UK announced that the fourth module of their national Covid-19 Inquiry will be rescheduled.
start at the beginning. this section of information concludes at the 4 minute mark, and goes on to an important discussion of 'Disease X.'
Tell it to the bankruptcy court judge. He obviously saw no cause to convert the case to CH7, which he should have done, if you guys are right about how worthless we are.
But you're right about the reaction we should have gotten from the clinical trials. The reaction we got from the Top Line Data should have indicated what to expect from the FDA decision.
The powers that be are losing control. Patients and doctors are not buying the mRNA vaccines as they were. It's time for lenz.
The $10K was the company's stated price for the therapeutic infusions.
I wondered about the cost of lenz, if used as a vaccine enhancement. Dosage and formulation of lenz for that application may be substantially less.
The vascular surgeon did two atherectomies in a procedure last year, leaving me with a long stent. I was supposed to have a follow-up visit with him last week, which was contingent on how much that was going to cost. The doctor's staff told me last week how much the insurance wouldn't pay, and I rescheduled the appointment. And yes, for the first time in my life, I began taking a few prescription drugs last year, as you surmised.
I hate to leave the house, but I have always hated leaving the house. It's just that this time, I drag my feet getting ready, until I finally succeed in becoming too late to go anywhere.
DTG, I don't interpret Durrant's comments as you do. I think the key is in what was not said. It does not consider the reasons why the bankruptcy court judge is discharging the case as a CH11. I'm glad that you recognize the potential of a looming recall of the loaned shares. But the magnitude of that impact, when it comes, will be far from some pittance for the poor Humanigen shareholders.
I'm not discounting the reasonableness of anyone who comes to that deduction. In fact, I recognize that my own estimation of the value of lenz in treating covid needs more than just an appreciation of the safety and efficacy of the product. The value I attach to lenz for covid requires a degree of necessity that that value comes to light. Now, that necessity is becoming exposed, by the deadly health effects of the mRNA vaccines. The medical community needs to see that lenz has a role in helping to prevent covid pneumonia infection, without contributing to excess deaths overall. They need to see that lenz is the best therapeutic capable of safely curing the infection, and that lenz can prevent future reoccurrences of covid.
I think the stage is set to showcase lenzilumab's role in fighting covid, both as a prophylaxis, and as a therapeutic. And I think Novavax may become the partner we need to establish control of the worldwide covid market. I think those steps must be taken, for the protection of the populace. And I believe those steps are being taken.